ERLEADA — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson ERLEADA — Sales to customers (Note 9) increased by 3.1% to $1.87B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 18.5%, from $1.58B to $1.87B. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market penetration or higher demand for the drug, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of ERLEADA, a pharmaceutical product used in the tr...
Peer comparison
Comparable to specific product line revenue metrics reported by other large-cap pharmaceutical companies for their key oncology or specialty drug assets.
jnj_segment_erleada_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $522.00M | $604.00M | $688.00M | $1.08B | $800.00M | $901.00M | $979.00M | $1.08B | $1.26B | $1.38B | $1.47B | $1.58B | $1.57B | $1.54B | $1.82B | $1.87B |
| QoQ Change | — | +15.7% | +13.9% | +57.3% | -26.1% | +12.6% | +8.7% | +10.7% | +16.3% | +9.3% | +6.8% | +7.3% | -0.8% | -1.7% | +17.8% | +3.1% |
| YoY Change | — | — | — | — | +53.3% | +49.2% | +42.3% | +35.5% | +40.0% | — | +35.8% | +25.3% | — | +11.9% | +23.4% | +18.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's erleada — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported erleada — sales to customers (note 9) of $1.87B in Q3 2025.
- How has Johnson & Johnson's erleada — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's erleada — sales to customers (note 9) increased by 18.5% year-over-year, from $1.58B to $1.87B.
- What does erleada — sales to customers (note 9) mean?
- The total net revenue generated from sales of the oncology drug ERLEADA.